Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Tecvvayli, Talvey, and Elrexfio demonstrate significant response rates and extended progression-free survival in heavily pretreated patients. Each bispecific antibody has a unique side effect profile, ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, ...

Cancer Monoclonal Antibody Market Cancer rates continue to rise, especially in aging populations and areas affected by pollution and lifest ...

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...